This report was first published by Endpoints News. To see the original version, click here
Cue Biopharma announced a reboot Thursday afternoon, bringing in notable biotech executive Shao-Lee Lin as well as a new allergy asset developed in Taiwan and mainland China.
The Boston-based biotech has focused on developing T cell modulators that could be used in both cancer and autoimmune disease, but it will now be jumping into a burgeoning allergy drug development field with an antibody that uses the same mechanism as the asthma medicine Xolair.
您已阅读24%（543字），剩余76%（1743字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。